Enveric Biosciences, Inc. Common Stock
$1.49
$0.03 (+2.05%)
$1.45Day Range$1.54
Key Statistics
Market Cap
$6.67M
Shares Outstanding
4.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 24, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$1.45
Day High
$1.54
Day Low
$1.45
Volume
52.1K
VWAP
$1.48
Prev Close
$1.46
Transactions
--
Acc. Volume
--
About Enveric Biosciences, Inc. Common Stock
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
PHARMACEUTICAL PREPARATIONSSIC 28346 employees245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA, 02142(617) 444-8400IPO Aug 24, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000890821
- Composite FIGI
- BBG000BBQ281
- Share Class FIGI
- BBG001S5W660
- Ticker Root
- ENVB
- SIC Code
- 2834
About Enveric Biosciences, Inc. Common Stock (ENVB) Stock
Enveric Biosciences, Inc. Common Stock (ENVB) closed the 2026-09-16 session at $1.49, up 2.05% versus the previous close (+0.03). The stock opened at $1.45 and traded between $1.45 and $1.54 during that session. Session trading volume was 52K shares. The volume-weighted average price (VWAP) is $1.48.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Enveric Biosciences, Inc. Common Stock has a market capitalization of $6.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ENVB is listed on the XNAS exchange. The company employs approximately 6 people. Enveric Biosciences, Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 1995-08-24.
On this page you can find market ENVB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.